Cibc World Market Inc. Raises Stock Holdings in AbbVie Inc. $ABBV

Cibc World Market Inc. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 10.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 657,272 shares of the company’s stock after acquiring an additional 60,635 shares during the quarter. Cibc World Market Inc.’s holdings in AbbVie were worth $152,185,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the 2nd quarter worth about $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the second quarter worth about $28,000. Financial Gravity Companies Inc. bought a new stake in AbbVie in the second quarter worth about $36,000. Delos Wealth Advisors LLC purchased a new position in AbbVie in the second quarter valued at about $39,000. Finally, Access Investment Management LLC bought a new position in shares of AbbVie during the 2nd quarter valued at approximately $44,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $222.32 on Wednesday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock has a market cap of $392.93 billion, a PE ratio of 94.20, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The stock has a fifty day moving average of $223.67 and a 200-day moving average of $220.29.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm’s revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on ABBV shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Scotiabank started coverage on AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. HSBC raised AbbVie from a “hold” rating to a “buy” rating and upped their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.